Literature DB >> 23138396

N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial.

Ricardo M Heguilén1, Amador A Liste, Miguel Payaslian, Martin Gabriel Ortemberg, Lautaro Martin Albarracín, Amelia Rita Bernasconi.   

Abstract

BACKGROUND: The occurrence of contrast-induced acute kidney injury (CIAKI) has paralleled the increased number of diagnostic interventions requiring radiographic contrast media (CM). Several strategies aimed at preventing renal injury following iodine have been carried out over the last several years. The aim of this study was to evaluate the impact of three different strategies aimed at preventing CIAKI in patients with renal dysfunction (serum creatinine >1.25 mg/dl or estimated creatinine clearance <45 ml/min) receiving low osmolar CM for diagnostic-therapeutic procedures.
METHODS: Candidates received 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h; the same schedule plus N-acethyl-cysteine (NAC) 600 mg twice daily the day before and the day of the procedure (BN) or NAC as above plus 154 mmol NaCl solution at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (SN). Serum creatinine (SCr) was measured at baseline and on days 2 or occasionally 3 after CM. The main outcome measure was the occurrence of CIAKI, defined as a ≥25% increase in SCr within 2-3 days of CM.
RESULTS: The three groups were similar with regard to age, gender distribution, weight, baseline serum levels of creatinine, sodium, potassium, urate and estimated creatinine clearance. A larger proportion of individuals received ACEIs/ARAs in the BN group (p < 0.05), but in the SN group, more patients declared a past history of acute myocardial infarction or had high blood pressure, and few displayed mild-moderate left ventricular dysfunction (p < 0.05). CIAKI occurred in 24/123 (19.5%) assessable patients (15/42 in the B0 group, 3/43 in the BN group and 6/38 in the SN group; p < 0.01). Thus, 15/42 patients who did not receive NAC developed CIAKI in contrast to 9/81 who did (p < 0.01). Multivariate logistic regression models showed that the use of NAC was the unique factor associated with a statistically significant influence for the occurrence of CIAKI (OR: 0.18; 95% CI: 0.04-0.72; p = 0.016).
CONCLUSIONS: The results from this study show that: (1) the occurrence of CIAKI after low-osmolar CM administration is similar to that reported worldwide. (2) NAC-based renoprotective measures are superior for the prevention of CIAKI in patients with previous renal dysfunction. (3) They also demonstrate that bicarbonate expansion alone has limited value in preventing CIAKI. For those individuals at risk, combination prophylaxis including volume expansion plus NAC should be recommended to reduce the chance of overt kidney injury following CM administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23138396     DOI: 10.1007/s10157-012-0722-3

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  57 in total

1.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.

Authors:  M Tepel; M van der Giet; C Schwarzfeld; U Laufer; D Liermann; W Zidek
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

2.  Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.

Authors:  P A McCullough; R Wolyn; L L Rocher; R N Levin; W W O'Neill
Journal:  Am J Med       Date:  1997-11       Impact factor: 4.965

Review 3.  Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney.

Authors:  S N Heyman; S Rosen; M Brezis
Journal:  Exp Nephrol       Date:  1994 May-Jun

Review 4.  Early diagnosis of acute kidney injury: the promise of novel biomarkers.

Authors:  Sachin S Soni; Claudio Ronco; Nevin Katz; Dinna N Cruz
Journal:  Blood Purif       Date:  2009-07-08       Impact factor: 2.614

5.  The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.

Authors:  Matthew J Kuhn; Nan Chen; Dushyant V Sahani; Dan Reimer; Edwin J R van Beek; Jay P Heiken; George J So
Journal:  AJR Am J Roentgenol       Date:  2008-07       Impact factor: 3.959

Review 6.  Contrast-induced nephropathy.

Authors:  G T C Wong; M G Irwin
Journal:  Br J Anaesth       Date:  2007-08-06       Impact factor: 9.166

Review 7.  Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

Authors:  Sankar D Navaneethan; Sonal Singh; Suresh Appasamy; Richard E Wing; Ashwini R Sehgal
Journal:  Am J Kidney Dis       Date:  2008-11-22       Impact factor: 8.860

8.  The prevention of radiocontrast-agent-induced nephropathy by hemofiltration.

Authors:  Giancarlo Marenzi; Ivana Marana; Gianfranco Lauri; Emilio Assanelli; Marco Grazi; Jeness Campodonico; Daniela Trabattoni; Franco Fabbiocchi; Piero Montorsi; Antonio L Bartorelli
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

9.  Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic.

Authors:  Aaron M From; Brian J Bartholmai; Amy W Williams; Stephen S Cha; Axel Pflueger; Furman S McDonald
Journal:  Clin J Am Soc Nephrol       Date:  2007-12-05       Impact factor: 8.237

Review 10.  N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis.

Authors:  Raymond Liu; Deepu Nair; Joachim Ix; Dan H Moore; Stephen Bent
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

View more
  3 in total

Review 1.  Current status of sodium bicarbonate in coronary angiography: an updated comprehensive meta-analysis and systematic review.

Authors:  Sadegh Ali-Hassan-Sayegh; Seyed Jalil Mirhosseini; Elham Rahimizadeh; Zahra Ghodratipour; Zahra Sarrafan-Chaharsoughi; Ali Mohammad Dehghan; Mohammad Reza Lotfaliani; Mohammad Rezaeisadrabadi; Elham Kayvanpour; Farbod Sedaghat-Hamedani; Mohamed Zeriouh; Alexander Weymann; Anton Sabashnikov; Aron-Frederik Popov
Journal:  Cardiol Res Pract       Date:  2015-04-21       Impact factor: 1.866

2.  Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.

Authors:  Khalid Ahmed; Terri McVeigh; Raminta Cerneviciute; Sara Mohamed; Mohammad Tubassam; Mohammad Karim; Stewart Walsh
Journal:  BMC Nephrol       Date:  2018-11-13       Impact factor: 2.388

Review 3.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.